Savara
SVRASavara Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare respiratory diseases.
Earnings
Next report
Aug 12, 2026 (in a month)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Savara Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare respiratory diseases. The company's primary focus is its lead product candidate, an investigational inhaled biologic designed to treat autoimmune pulmonary alveolar proteinosis (aPAP) by restoring lung macrophage function. Savara utilizes a capital-efficient business model by outsourcing manufacturing and clinical development to specialized third-party vendors.
Savara is developing the largest placebo-controlled trial in autoimmune PAP and holds multiple regulatory designations including Breakthrough Therapy and Orphan Drug status.
Questions, answered.
- What is Savara's market cap?
- Savara (SVRA) has a market capitalization of $1.3B and trades on NASDAQ.
- Who are Savara's competitors?
- Savara's key competitors include Edesa Biotech, Inc. Common Shares, Zevra Therapeutics, Inc. Common Stock, Pulmatrix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Savara partner with?
- Savara's notable partners include PARI Pharma GmbH, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., and others.
- Where is Savara headquartered?
- Savara is headquartered in United States of America and employs approximately 37 people. It has been publicly traded since 1996.